[{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Arbormentis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Esmethadone Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relmada Therapeutics \/ Arbormentis","highestDevelopmentStatusID":"10","companyTruncated":"Relmada Therapeutics \/ Arbormentis"}]

Find Clinical Drug Pipeline Developments & Deals for Esmethadone Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : REL-1017 (esmethadone) NMDA receptor inhibitor, small molecule drug candidate, which is being evaluated as an adjunct treatment for the treatment of major depressive disorder.

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 09, 2024

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : REL-1017 is a NCE and novel NMDAR channel blocker that targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, in major depressive disorder patients.

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : In the study, the REL-1017 treatment arm showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for the placebo arm, a higher than expected placebo response.

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 13, 2022

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : REL-1017, a new chemical entity and novel NMDA receptor channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of major de...

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 12, 2022

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : REL-1017 (esmethadone), new chemical entity and novel NMDA receptor channel blocker preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, in late-stage development for treatment of major depressive d...

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2022

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatme...

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 29, 2022

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatme...

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 04, 2022

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg and 150 mg) tested in recreational opioid users, demonstrated a highly statistically significant difference vs. the active control drug, oxycodone 40 mg.

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 27, 2021

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : $15.0 million

                          July 20, 2021

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Undisclosed

                          Sponsor : Arbormentis

                          Deal Size : $165.0 million

                          Deal Type : Acquisition

                          blank

                          10

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development as an adjunctive treatment for MDD in adults.

                          Product Name : REL-1017

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 15, 2021

                          Lead Product(s) : Esmethadone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank